Recursion unveils post-combination technology-enabled portfolio with more than 10 clinical and preclinical programs, 10 advanced discovery programs, and more than 10 partnered programsPlatform ...

Aktien»Nachrichten»RECURSION PHARMACEUTICALS AKTIE» RECURSION PHARMACEUTICALS INC WKN: A3CM1C|ISIN: US75629V1044|Ticker-Symbol: NASDAQ 11.04.25 21:59 5,745 +1,235+27,38 % Nachrichten Analysen ...

First program to combine Recursion’s end-to-end suite of AI-enabled active learning modules, resulting in target identification to IND enabling studies in under 18 monthsPlan to initiate dosing ...

Salt Lake City, UT, July 08, 2025 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX) a leading clinical stage TechBio company decoding biology to radically improve lives today announced the acquisition ...

Recursion Acquires Full Rights to REV102, a Potential First-in-Class Oral ENPP1 Inhibitor for Hypophosphatasia Provided by GlobeNewswire Jul 8, 2025, 5:00:00 AM ...

Recursion Acquires Full Rights to REV102, a Potential First-in-Class Oral ENPP1 Inhibitor for Hypophosphatasia Recursion Pharmaceuticals - GlobeNewswire - Tue Jul 8, 7:00AM CDT ...

Recursion Acquires Full Rights to REV102, a Potential First-in-Class Oral ENPP1 Inhibitor for Hypophosphatasia () | aktiencheck.deRecursion Acquires Full Rights to REV102, a Potential First-in ...